OBJECTIVE: @entity5052 is strongly associated with @entity28 and @entity209 and can predict @entity1144 and insulin resistance. Previously, we showed that soluble @entity414 directly stimulated the redox-dependent proinflammatory signaling in adipocytes. In this study we demonstrate the role of @entity5052 in the production of key adipokines. RESEARCH DESIGN AND METHODS: We used @entity19 3T3-L1 adipocytes, @entity1 primary adipocytes, and a @entity19 model of @entity209 and @entity5052 . RESULTS: @entity414 induced in vitro an increase in the production (mRNA and secreted protein) of @entity1750 ( @entity1750 ), an adipokine playing an essential role in inducing the proinflammatory state in adipocytes in @entity28 . In addition, @entity414 caused a decrease in the production of adiponectin, an adipocyte-specific insulin sensitizer and anti-inflammatory agent. @entity414 -induced increase in @entity1750 production was blocked by scavenging @entity224 or by inhibiting @entity1110 oxidase and by stimulating peroxisome-proliferator-activated receptor-y with @entity6170 . Downregulation of the adiponectin production was prevented by @entity6170 but not by antioxidants. In @entity28 @entity19 with @entity209 , we observed @entity5052 . Lowering @entity414 in these @entity19 by inhibiting @entity3624 oxidoreductase with @entity208 could improve the proinflammatory endocrine imbalance in the adipose tissue by reducing production of @entity1750 and increasing production of adiponectin. In addition, lowering @entity414 in @entity28 @entity19 decreased macrophage infiltration in the adipose tissue and reduced insulin resistance. CONCLUSIONS: @entity5052 might be partially responsible for the proinflammatory endocrine imbalance in the adipose tissue, which is an underlying mechanism of the low-grade @entity32 and insulin resistance in subjects with the @entity209 .

@entity5052 as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a XXXX model of the @entity209 .

@entity1 :: ('9606', 'Species') :: ['human'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity'] @entity1750 :: ('20296(Tax:10090)', 'Gene') :: ['MCP-1', 'monocyte chemotactic protein-1'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity3624 :: ('MESH:D019820', 'Chemical') :: ['xanthine'] @entity1110 :: ('MESH:D009249', 'Chemical') :: ['NADPH'] @entity1144 :: ('MESH:D056128', 'Disease') :: ['visceral obesity'] @entity208 :: ('MESH:D000493', 'Chemical') :: ['allopurinol'] @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia', 'Hyperuricemia'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome'] @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide'] @entity6170 :: ('MESH:C089730', 'Chemical') :: ['rosiglitazone'] @entity414 :: ('MESH:D014527', 'Chemical') :: ['Uric acid', 'uric acid']
@entity19 :: (10090,Species) :: ['murine']
